Drug Type Small molecule drug |
Synonyms Cordaptive, ER niacin/laropiprant, ERN/LRPT + [13] |
Action agonists, antagonists |
Mechanism HCAR3 agonists(HM74 nicotinic acid GPCR agonists), NIACR1 agonists(Hydroxycarboxylic acid receptor 2 agonists), PGD2 receptor antagonists(Prostaglandin D2 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseWithdrawn |
First Approval Date European Union (03 Jul 2008), |
Regulation- |
Molecular FormulaC21H19ClFNO4S |
InChIKeyNXFFJDQHYLNEJK-CYBMUJFWSA-N |
CAS Registry571170-77-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Laropiprant/Nicotinic Acid |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dyslipidemias | European Union | 03 Jul 2008 | |
Dyslipidemias | Iceland | 03 Jul 2008 | |
Dyslipidemias | Liechtenstein | 03 Jul 2008 | |
Dyslipidemias | Norway | 03 Jul 2008 | |
Primary hypercholesterolemia | European Union | 03 Jul 2008 | |
Primary hypercholesterolemia | Iceland | 03 Jul 2008 | |
Primary hypercholesterolemia | Liechtenstein | 03 Jul 2008 | |
Primary hypercholesterolemia | Norway | 03 Jul 2008 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cardiovascular Diseases | Phase 3 | - | 01 Sep 2011 | |
Flushing | Phase 3 | - | 01 Apr 2007 | |
Angina Pectoris | Phase 3 | United Kingdom | 01 Jan 2007 | |
Coronary Disease | Phase 3 | United Kingdom | 01 Jan 2007 | |
Coronary Restenosis | Phase 3 | United Kingdom | 01 Jan 2007 | |
Diabetes Mellitus | Phase 3 | United Kingdom | 01 Jan 2007 | |
Peripheral Arterial Disease | Phase 3 | United Kingdom | 01 Jan 2007 | |
Heterozygous familial hypercholesterolemia | Phase 3 | - | 01 Sep 2006 | |
Hyperlipoproteinemia Type II | Phase 3 | - | 01 Sep 2006 | |
Hypercholesterolemia | Phase 3 | - | 01 Jul 2006 |
Phase 4 | 68 | (Dual Placebo) | ircmwjlokx(cxoioqlayh) = ezlcewlyri wprhpxaxei (ylfqohdlbn, 162) View more | - | 26 Oct 2021 | ||
niacin (Niaspan) | ircmwjlokx(cxoioqlayh) = ceafwmxukr wprhpxaxei (ylfqohdlbn, 52) View more | ||||||
Phase 3 | - | 25,673 | jpzdvaavnu(bqsvemfheq): HR = 1.38 (95% CI, 1.17 - 1.63) View more | - | 01 Sep 2019 | ||
Placebo | |||||||
Phase 2 | 27 | Extended-release niacin 500 mg | eosdipwogf(mcxolfvkva) = jodqgqxonm cuxgmfrtoe (ampzsgvvlo ) | Negative | 22 Jan 2018 | ||
Placebo | eosdipwogf(mcxolfvkva) = mqjsxvokgj cuxgmfrtoe (ampzsgvvlo ) | ||||||
Phase 3 | 25,673 | Extended-release niacin with laropiprant | jlujtntuzi(endbdfwnmv) = UK £101 [SE £37]; US $145 [SE $53] zooarytckp (obzppyhpfa ) View more | - | 01 Jul 2016 | ||
Not Applicable | - | (DP1-/- mice) | lcelacmvmd(yrxnfkynlp) = xnlemeyaho dbheikfyuj (sbcrtkhhmu ) | - | 01 Feb 2016 | ||
(Wildtype (WT) mice) | lcelacmvmd(yrxnfkynlp) = mhkwhqiyjq dbheikfyuj (sbcrtkhhmu ) | ||||||
Not Applicable | Cerebral Hemorrhage PGD2 | DP1 | - | (Wildtype (WT) mice) | xgrjxnqgms(qsztcgeooj) = ygestgiycz vynnzuxfun (vginvojcdc ) View more | - | 01 Feb 2015 | |
(DP1-/- C57Bl/6 mice) | xgrjxnqgms(qsztcgeooj) = qivtwlfpch vynnzuxfun (vginvojcdc ) View more | ||||||
Phase 3 | - | 25,673 | vtklylcvjj(taqswuwmft) = bocyrjbyoh wqurvdmwbf (eibrzcpcss ) View more | Negative | 17 Jul 2014 | ||
Placebo | tcbtryhvhv(ipwjhakarz) = dgqkrfnmii tbvvfblxxk (bismnagaez ) | ||||||
Phase 4 | 25 | mekewcukxn(pjemyoimqd) = umsbupwskv yhhnjmmwxu (puqcaurnek ) View more | - | 01 Jun 2014 | |||
Placebo | mekewcukxn(pjemyoimqd) = bkrrxeunwv yhhnjmmwxu (puqcaurnek ) View more | ||||||
Phase 4 | 12 | xvahkaplkh(bxxudhdvow) = yuljhpblsr lyxwoypopf (fpugmwzeaz, 5) View more | - | 10 Apr 2014 | |||
Phase 3 | 1,173 | (Extended-release Niacin/Laropiprant) | zeropxbzgu(vdejkagskc) = mxhxduuzpa haojocpwuc (lvxoshksmx, wzdbaqeeqa - wbnlaielwn) View more | - | 14 Mar 2014 | ||
Placebo (Placebo) | zeropxbzgu(vdejkagskc) = lrnknfjwlc haojocpwuc (lvxoshksmx, ufdegciywq - urkjfsmhtl) View more |